Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models

Table 2

Effects of inhibitors of enzymes that degrade endocannabinoids in animal models of CINP.

CINP model		Inhibitor of enzymes that degrade endocannabinoids	Effects	Effects of CB receptor antagonists on the activity of the compound	Reference
Chemotherapy drug	Animal
Vincristine	Male SD rats	FAAH inhibitor ST4070	Suppressed established mechanical allodynia	No antagonists were used against vincristine	[28]
Cisplatin	Male C3H/HeN mice	FAAH inhibitor URB597	Delayed the onset and decreased the magnitude of mechanical and heat hyperalgesia	CB1 antagonist AM281 antagonised	[25]
			Suppressed established mechanical and thermal hyperalgesia	CB2 antagonist AM630 had no effect
Cisplatin	Male SD rats	FAAH inhibitors URB597 and URB937	Suppressed established mechanical and cold allodynia	CB1 antagonist AM251 antagonised	[24]
		MGL inhibitor JZL184		CB2 antagonist AM630 had no effect
Cisplatin	Male C3H/HeN mice	MGL inhibitor JZL184	Prevented the development of mechanical hyperalgesia	CB1 receptor antagonist AM281 antagonised	[26]
			Suppressed established mechanical allodynia	CB2 receptor antagonist AM630 had no effect
Paclitaxel	Male CD1 and C57BL/6J mice	URB597 and JZL184	Suppressed mechanical and cold allodynia	Antagonists were not tested	[29]

FAAH, fatty acid amide hydrolase; MGL, monoacylglycerol lipase; SD, Sprague-Dawley.